Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm reports ind application update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm submits responses to US FDA questions
- Paradigm receives key regulatory approvals for mps vi study
- Ind questions received from US FDA
- Paradigm achieves first revenue
- Paradigm provides ind application update
Later from Paradigm Biopharmaceuticals
- 2021 Annual Report and Appendix 4E
- Aus ethics approval received for phase 3 trial
- Paradigm receives feedback from US FDA on ind submission
- First mps-vi patient dosed under phase 2 trial in Brazil
- Positive top-line results from preclinical study in ards
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals